Deleted Tweets From Scott Gottlieb, R-D.C.

RT @ASCOPost: "We’re commited to enhancing transparency about the work we do at the FDA, especially when it has the potential to… https://t.co/uGGw2c6ic5

RT @FDAfood: #Physicians you're a very important component to combating the spread of #foodborne illness – Suspect, Identify, Tr… https://t.co/zBjlkAzZ22

RT @FDAcdrhIndustry: FDA issues final rule on “Human Subject Protection; Acceptance of Data from Clinical Investigations for Medical Dev… https://t.co/AgjMdoqidM

RT @FDAOncology: Webcast happening now: https://t.co/CjmxwEg0eL https://t.co/2DYEoK0RNh QT @DrAJWalker: Great discussion / debate at #RxRTCombos18 regarding the importance of preclinical data. And then Paul Harari broug… https://t.co/X4VJ6dShdV)

RT @dgingery: Thursday morning reading: Gottlieb's Priority For Proposed Opioid Money Is Mail Facilities https://t.co/9ftTFN9JGK

#FDA and AMA launched a new video to empower consumers to help prevent foodborne illness when storing, preparing and serving food:https://t.co/We2DCgWyAK https://t.co/CkjLZvCq5Y

“These new provisions and FDA’s draft guidance will hopefully provide greater clarity to sponsors about how to demonstrate that clinical data collected from clinical investigations conducted OUS are adequate under FDA’s standards.” https://t.co/qT6ALBEc4B QT @fdalawblog: FDA Publishes Final Rule and Draft Guidance on Acceptance of Clinical Data to Support Medical Device Applications a… https://t.co/LXTjcBCk6P)

The @US_FDA is grateful for the public health leadership of @Surgeon_General Adams in his efforts to promote smoking cessation and alternatives to combustible cigarettes to address nicotine addiction https://t.co/cb4bAZ3chr

RT @FDATobacco: FDA Commissioner @SGottliebFDA and CTP Director Mitch Zeller will discuss FDA’s comprehensive plan on tobacco and n… https://t.co/widrMuXfmP

RT @steveusdin1: FDA planning pilot program for innovative trial designs https://t.co/38wxWJ1QuH

RT @FDAMedia: Statement from Stephen Ostroff M.D., Deputy Commissioner for Foods and Veterinary Medicine, on National Toxicology… https://t.co/FSykB5AXgM

RT @FDATobacco: At #SRNT2018, FDA Commissioner @SGottliebFDA and CTP Director Mitch Zeller discussed FDA’s comprehensive plan on to… https://t.co/Bl6oKQIAID

Ultimately, the best approaches are the ones that help the most people possible quit combustible tobacco, and quit for good. That starts with good research into what works; and how #FDA can support those scientifically proven goals with sound regulatory p QT @Clive_Bates: Quitting smoking with NRT, Rx or cold turkey almost always involves dual use: serial quit then relapse, quit, relap… https://t.co/sE8p6eQXNd)

I want to thank my hosts at @srntorg for their hospitality today; for their science based research that informs #FDAs work and a thoughtful public dialogue on issues of smoking cessation; and for their rigorous adherence to protecting kids from tobacco an

As a science-based agency, NCTR’s expert work is essential to #FDA’s efforts in public health. Our committed NCTR colleagues provide important research and analysis to support FDA’s regulatory decision-making and critical consumer protection mission. http

My remarks today on tobacco cessation, science based research, and #FDA’s mission to advance public health through its comprehensive approach to tobacco regulation before @srntorg https://t.co/L2zZJrfYG3

RT @SecAzar: Today, I happily accepted @CDCDirector's #MoveWithHeart challenge, which shines light on the important issue of… https://t.co/isldrjABO9

NPR: Plastic Additive BPA Not Much Of A Threat, Government Study Finds: “A two-year government study of rats found that even high doses of the plastic additive produced only "minimal effects," and that these effects could have occurred by chance. https://

RT @AP_FDAwriter: FDA statement on new BPA draft study: "Our initial review supports our determination that currently authorized uses… https://t.co/lEpgjGqiyj

#FDA intends to launch by year end a pilot program for complex innovative designs of clinical trials. FDA will seek input on program at a public meeting March 20, and publish draft guidance within 18 months of the meeting. https://t.co/OH282mrRsW

Today, NTP published draft report on BPA. Study conducted by senior scientists at FDA’s NCTR--part of collaborative effort between federal agencies, academic grantees. #FDA continues to conclude BPA is safe for its currently authorized uses: https://t.co/

An interesting use of a good challah by @Farzad_MD. While the ingredients are subject to regulation, the preparation - or whatever was done is this case - is subject to my friend’s personal discretion. https://t.co/d9oioKD2hn QT @Farzad_MD: @daviesbj This challah is fried in foie gras fat https://t.co/AQAjYPN74Z)

New minimum performance requirements that #FDA implemented for antigen-based #flu tests are expected to lower the number of misdiagnosed flu infections by promoting the development of new, improved devices that can more reliably detect the influenza virus

#FDA looks at all available scientific evidence when reviewing safety of foods & food packaging & regularly collaborates w/other federal partners to protect; promote public health. Read about robust research conducted by FDA NCTR senior scientists

Our initial review of NTP draft report on BPA supports #FDA’s determination that currently authorized uses of BPA continue to be safe for consumers. It builds upon the already extensive data collected in our 2014 BPA assessment: https://t.co/JVBvVBUtoo

RT @ABucaida: Keynoter Dr. @SGottliebFDA keynoted @srntorg Annual Meeting. Full video is available at SRNT's new YouTube channel.… https://t.co/AjaT01zIrQ

Manufacturers had until Jan 12, 2018 to come into compliance. Of additional note, #FDA recommends that clinical decisions be made based on signs and symptoms consistent with the #flu and not simply rely on a test, even an accurate one.

@DShaywitz @anobelodisho @daviesbj @AkikoaCom @Farzad_MD @WholeFoods If the recipe is to simple fry it in duck fat, like @Farzad_MD’s food instructions call for, then it’s probably ok if the bread is a little, I dare say, stale; don’t you think @DShaywitz

RT @SGottliebFDA: @DShaywitz @anobelodisho @daviesbj @AkikoaCom @Farzad_MD @WholeFoods If the recipe is to simple fry it in duck fat,… https://t.co/2zw2nv1OEu

Among the new initiatives that we’re pursuing in the @POTUS FY 2019 budget for #FDA are resources to expand our digital health Pre-Cert program that creates a new paradigm for the advancement of properly regulated, beneficial new digital health tools http

Check out the latest issue of the FDA Patient Network Newsletter and sign up for FDA information https://t.co/aigsuJODIw https://t.co/zWkU8gpI3l

@daviesbj @DShaywitz @anobelodisho @AkikoaCom @Farzad_MD @WholeFoods Drs. @DShaywitz @Farzad_MD @daviesbj et. al. - In consideration of @daviesbj’s recipie (portions highlighted below) I provide a link to #FDA’s recommendations on added salt https://t.co/

Today @SecAzar speaking at the @NatlGovsAssoc on the commitment of @HHSGov to support those confronting opioid addiction and his commitment to #FDA’s mission to develop safe and effective medical therapy to help people seeking lives free from addiction ht

As part of #FDA’s 2019 budget we’re investing in an expansion of continuous manufacturing by drug makers to domesticate U.S. production; ensure reliability of supply; reduce shortages; make it easier to respond to crises like flu with rapid vaccine scale

#FDA’s FY 2019 budget request from @POTUS includes resources for a new initiative on continuous manufacturing that will improve the reliability; timeliness; effectiveness of #flu vaccine manufacturing using modern cell based and recombinant technologies h

RT @FDA_ORA: #MostWantedMonday Stephen Mark Van Rooyen is wanted by #FDAORA #OCI for selling #stemcells & stem cell injections i… https://t.co/tu5VppTUyh

Ending an “addiction” is separate from achieving “total abstinence”. Someone may be on lifelong replacement therapy with an approved opioid agonist; but no longer be “addicted” to opioids. Psychological addiction is not synonymous with physical dependence

My statement on what #FDA is learning about the efficacy of this year’s #flu vaccine; and the agency’s ongoing efforts to apply these findings to help improve the effectiveness of future influenza vaccines: https://t.co/NNpr8eBO1l https://t.co/zV6xWQzmyb

#FDA announced a new orphan drug pilot that will include a new form intended to make the submission process easier for sponsors to complete orphan designation requests, and to make the process more efficient for FDA https://t.co/hnBw9Zqh6c

RT @US_FDA: FDA Commissioner @SGottliebFDA re: new steps we’re taking to meet the challenges of rare diseases. #rarediseaseday… https://t.co/7hTGwebPBX

I’m pleased to announce new @US_FDA efforts to support rare disease therapies #rarediseaseday: https://t.co/qqP2ibvwn7

At a May 9th meeting on drugs that treat rare cancers; we'll discuss cancer therapies that target a tumor’s specific genetic features rather than its location in body (tissue agnostic approvals) and how we treat these products under the orphan drug progra

My update today on what #FDA is learning about the potential root cause for why this year’s #flu vaccine showed diminished efficacy against the season’s predominant H3N2 strain of influenza https://t.co/NNpr8eBO1l https://t.co/134Khj6ZAM

RT @sjtribble: FDA's @SGottliebFDA announces a new pilot, a public meeting, and a memorandum of understanding w/ @RareDiseases as… https://t.co/V55pkUFD7v

#FDA is using what it’s learning about the potential root cause for why this year’s #flu vaccine showed diminished efficacy against the season’s H3N2 strain of flu to prepare for next season and improve vaccine development https://t.co/Sbxx3fN1eH

RT @RAPSorg: .@US_FDA to Launch New Pilot Program for Orphan Designation Requests | #Regulatory Focus https://t.co/zOXAFxQYVD… https://t.co/1pDMWpMXrb

RT @US_FDA: We have developed a series of new videos and other materials that explain the scope of what FDA is doing to encoura… https://t.co/8J6k8O3YYE

RT @FDAOncology: .@FDAOncology perspective: Evaluating Endpoints & Evidence in Era of Breakthrough Therapies @OncJournal https://t.co/NuD9lM1qoz

RT @RAPSorg: .@US_FDA Considers a Shift on #MedDevice Quality System Regulations | #Regulatory Focus https://t.co/CVE4btXaEv #FDA https://t.co/IrNNIJ8dlX

#FDA is working to improve #flu vaccine efficacy ; find the root cause of this year’s diminished effectiveness against H3N2 https://t.co/pQtJm97apc

RT @ASCOPost: "We’re commited to enhancing transparency about the work we do at the FDA, especially when it has the potential to… https://t.co/uGGw2c6ic5

RT @FDAfood: #Physicians you're a very important component to combating the spread of #foodborne illness – Suspect, Identify, Tr… https://t.co/zBjlkAzZ22

RT @FDAcdrhIndustry: FDA issues final rule on “Human Subject Protection; Acceptance of Data from Clinical Investigations for Medical Dev… https://t.co/AgjMdoqidM

RT @FDAOncology: Webcast happening now: https://t.co/CjmxwEg0eL https://t.co/2DYEoK0RNh QT @DrAJWalker: Great discussion / debate at #RxRTCombos18 regarding the importance of preclinical data. And then Paul Harari broug… https://t.co/X4VJ6dShdV)

RT @dgingery: Thursday morning reading: Gottlieb's Priority For Proposed Opioid Money Is Mail Facilities https://t.co/9ftTFN9JGK

#FDA and AMA launched a new video to empower consumers to help prevent foodborne illness when storing, preparing and serving food:https://t.co/We2DCgWyAK https://t.co/CkjLZvCq5Y

“These new provisions and FDA’s draft guidance will hopefully provide greater clarity to sponsors about how to demonstrate that clinical data collected from clinical investigations conducted OUS are adequate under FDA’s standards.” https://t.co/qT6ALBEc4B QT @fdalawblog: FDA Publishes Final Rule and Draft Guidance on Acceptance of Clinical Data to Support Medical Device Applications a… https://t.co/LXTjcBCk6P)

The @US_FDA is grateful for the public health leadership of @Surgeon_General Adams in his efforts to promote smoking cessation and alternatives to combustible cigarettes to address nicotine addiction https://t.co/cb4bAZ3chr

RT @FDATobacco: FDA Commissioner @SGottliebFDA and CTP Director Mitch Zeller will discuss FDA’s comprehensive plan on tobacco and n… https://t.co/widrMuXfmP

RT @steveusdin1: FDA planning pilot program for innovative trial designs https://t.co/38wxWJ1QuH

RT @FDAMedia: Statement from Stephen Ostroff M.D., Deputy Commissioner for Foods and Veterinary Medicine, on National Toxicology… https://t.co/FSykB5AXgM

RT @FDATobacco: At #SRNT2018, FDA Commissioner @SGottliebFDA and CTP Director Mitch Zeller discussed FDA’s comprehensive plan on to… https://t.co/Bl6oKQIAID

Ultimately, the best approaches are the ones that help the most people possible quit combustible tobacco, and quit for good. That starts with good research into what works; and how #FDA can support those scientifically proven goals with sound regulatory p QT @Clive_Bates: Quitting smoking with NRT, Rx or cold turkey almost always involves dual use: serial quit then relapse, quit, relap… https://t.co/sE8p6eQXNd)

I want to thank my hosts at @srntorg for their hospitality today; for their science based research that informs #FDAs work and a thoughtful public dialogue on issues of smoking cessation; and for their rigorous adherence to protecting kids from tobacco an

As a science-based agency, NCTR’s expert work is essential to #FDA’s efforts in public health. Our committed NCTR colleagues provide important research and analysis to support FDA’s regulatory decision-making and critical consumer protection mission. http

My remarks today on tobacco cessation, science based research, and #FDA’s mission to advance public health through its comprehensive approach to tobacco regulation before @srntorg https://t.co/L2zZJrfYG3

RT @SecAzar: Today, I happily accepted @CDCDirector's #MoveWithHeart challenge, which shines light on the important issue of… https://t.co/isldrjABO9

NPR: Plastic Additive BPA Not Much Of A Threat, Government Study Finds: “A two-year government study of rats found that even high doses of the plastic additive produced only "minimal effects," and that these effects could have occurred by chance. https://

RT @AP_FDAwriter: FDA statement on new BPA draft study: "Our initial review supports our determination that currently authorized uses… https://t.co/lEpgjGqiyj

#FDA intends to launch by year end a pilot program for complex innovative designs of clinical trials. FDA will seek input on program at a public meeting March 20, and publish draft guidance within 18 months of the meeting. https://t.co/OH282mrRsW

Today, NTP published draft report on BPA. Study conducted by senior scientists at FDA’s NCTR--part of collaborative effort between federal agencies, academic grantees. #FDA continues to conclude BPA is safe for its currently authorized uses: https://t.co/

An interesting use of a good challah by @Farzad_MD. While the ingredients are subject to regulation, the preparation - or whatever was done is this case - is subject to my friend’s personal discretion. https://t.co/d9oioKD2hn QT @Farzad_MD: @daviesbj This challah is fried in foie gras fat https://t.co/AQAjYPN74Z)

New minimum performance requirements that #FDA implemented for antigen-based #flu tests are expected to lower the number of misdiagnosed flu infections by promoting the development of new, improved devices that can more reliably detect the influenza virus

#FDA looks at all available scientific evidence when reviewing safety of foods & food packaging & regularly collaborates w/other federal partners to protect; promote public health. Read about robust research conducted by FDA NCTR senior scientists

Our initial review of NTP draft report on BPA supports #FDA’s determination that currently authorized uses of BPA continue to be safe for consumers. It builds upon the already extensive data collected in our 2014 BPA assessment: https://t.co/JVBvVBUtoo

RT @ABucaida: Keynoter Dr. @SGottliebFDA keynoted @srntorg Annual Meeting. Full video is available at SRNT's new YouTube channel.… https://t.co/AjaT01zIrQ

Manufacturers had until Jan 12, 2018 to come into compliance. Of additional note, #FDA recommends that clinical decisions be made based on signs and symptoms consistent with the #flu and not simply rely on a test, even an accurate one.

@DShaywitz @anobelodisho @daviesbj @AkikoaCom @Farzad_MD @WholeFoods If the recipe is to simple fry it in duck fat, like @Farzad_MD’s food instructions call for, then it’s probably ok if the bread is a little, I dare say, stale; don’t you think @DShaywitz

RT @SGottliebFDA: @DShaywitz @anobelodisho @daviesbj @AkikoaCom @Farzad_MD @WholeFoods If the recipe is to simple fry it in duck fat,… https://t.co/2zw2nv1OEu

Among the new initiatives that we’re pursuing in the @POTUS FY 2019 budget for #FDA are resources to expand our digital health Pre-Cert program that creates a new paradigm for the advancement of properly regulated, beneficial new digital health tools http

Check out the latest issue of the FDA Patient Network Newsletter and sign up for FDA information https://t.co/aigsuJODIw https://t.co/zWkU8gpI3l

@daviesbj @DShaywitz @anobelodisho @AkikoaCom @Farzad_MD @WholeFoods Drs. @DShaywitz @Farzad_MD @daviesbj et. al. - In consideration of @daviesbj’s recipie (portions highlighted below) I provide a link to #FDA’s recommendations on added salt https://t.co/

Today @SecAzar speaking at the @NatlGovsAssoc on the commitment of @HHSGov to support those confronting opioid addiction and his commitment to #FDA’s mission to develop safe and effective medical therapy to help people seeking lives free from addiction ht

As part of #FDA’s 2019 budget we’re investing in an expansion of continuous manufacturing by drug makers to domesticate U.S. production; ensure reliability of supply; reduce shortages; make it easier to respond to crises like flu with rapid vaccine scale

#FDA’s FY 2019 budget request from @POTUS includes resources for a new initiative on continuous manufacturing that will improve the reliability; timeliness; effectiveness of #flu vaccine manufacturing using modern cell based and recombinant technologies h

RT @FDA_ORA: #MostWantedMonday Stephen Mark Van Rooyen is wanted by #FDAORA #OCI for selling #stemcells & stem cell injections i… https://t.co/tu5VppTUyh

Ending an “addiction” is separate from achieving “total abstinence”. Someone may be on lifelong replacement therapy with an approved opioid agonist; but no longer be “addicted” to opioids. Psychological addiction is not synonymous with physical dependence

My statement on what #FDA is learning about the efficacy of this year’s #flu vaccine; and the agency’s ongoing efforts to apply these findings to help improve the effectiveness of future influenza vaccines: https://t.co/NNpr8eBO1l https://t.co/zV6xWQzmyb

#FDA announced a new orphan drug pilot that will include a new form intended to make the submission process easier for sponsors to complete orphan designation requests, and to make the process more efficient for FDA https://t.co/hnBw9Zqh6c

RT @US_FDA: FDA Commissioner @SGottliebFDA re: new steps we’re taking to meet the challenges of rare diseases. #rarediseaseday… https://t.co/7hTGwebPBX

I’m pleased to announce new @US_FDA efforts to support rare disease therapies #rarediseaseday: https://t.co/qqP2ibvwn7

At a May 9th meeting on drugs that treat rare cancers; we'll discuss cancer therapies that target a tumor’s specific genetic features rather than its location in body (tissue agnostic approvals) and how we treat these products under the orphan drug progra

My update today on what #FDA is learning about the potential root cause for why this year’s #flu vaccine showed diminished efficacy against the season’s predominant H3N2 strain of influenza https://t.co/NNpr8eBO1l https://t.co/134Khj6ZAM

RT @sjtribble: FDA's @SGottliebFDA announces a new pilot, a public meeting, and a memorandum of understanding w/ @RareDiseases as… https://t.co/V55pkUFD7v

#FDA is using what it’s learning about the potential root cause for why this year’s #flu vaccine showed diminished efficacy against the season’s H3N2 strain of flu to prepare for next season and improve vaccine development https://t.co/Sbxx3fN1eH

RT @RAPSorg: .@US_FDA to Launch New Pilot Program for Orphan Designation Requests | #Regulatory Focus https://t.co/zOXAFxQYVD… https://t.co/1pDMWpMXrb

RT @US_FDA: We have developed a series of new videos and other materials that explain the scope of what FDA is doing to encoura… https://t.co/8J6k8O3YYE

RT @FDAOncology: .@FDAOncology perspective: Evaluating Endpoints & Evidence in Era of Breakthrough Therapies @OncJournal https://t.co/NuD9lM1qoz

RT @RAPSorg: .@US_FDA Considers a Shift on #MedDevice Quality System Regulations | #Regulatory Focus https://t.co/CVE4btXaEv #FDA https://t.co/IrNNIJ8dlX

#FDA is working to improve #flu vaccine efficacy ; find the root cause of this year’s diminished effectiveness against H3N2 https://t.co/pQtJm97apc